Omentin-1 supplementation and pharmacological inhibition of FABP4 were shown to reduce atherosclerotic plaque formation in an apolipoprotein E (ApoE)-deficient animal model of atherosclerosis (Fernández-Trasancos et al., 2017; Rodríguez-Calvo et al., 2017). This evidence concerns the gene FABP4 and atherosclerosis.